Aspirin and esomeprazole are superior to clopidogrel in preventing recurrent ulcer bleeding

Area of Science:

• Gastroenterology
• Cardiology
• Pharmacology

Background:

• Low-dose aspirin is a common antiplatelet agent for preventing ischemic events.
• Clopidogrel is considered potentially superior to aspirin for ischemic event prevention.
• Proton pump inhibitors (PPIs) or clopidogrel substitution are options for aspirin-intolerant patients.

Purpose of the Study:

• To compare the efficacy of clopidogrel versus aspirin plus esomeprazole in preventing recurrent ulcer bleeding.
• To evaluate the safety and effectiveness of dual therapy in patients with a history of gastrointestinal ulcers.

Main Methods:

• A randomized trial involving patients with healed ulcers.
• Participants received either clopidogrel 75 mg/day or aspirin 80 mg/day with esomeprazole 20 mg twice daily for 12 months.
• Recurrent ulcer bleeding was the primary endpoint, confirmed endoscopically.

Main Results:

• Fourteen cases of recurrent ulcer bleeding were confirmed.
• 13 of 161 patients (8.1%) on clopidogrel experienced recurrent bleeding.
• Only 1 of 159 patients (0.6%) on aspirin plus esomeprazole had recurrent bleeding.

Conclusions:

• The combination of aspirin and esomeprazole is significantly superior to clopidogrel in preventing recurrent ulcer bleeding in patients with a history of ulcers.
• This finding suggests a critical role for acid suppression in mitigating bleeding risk with antiplatelet therapy.
• Further research could explore comparative effectiveness of aspirin and clopidogrel when co-administered with esomeprazole.